Citations

Clear

9383 citation(s) found for "Thomas, PS".

Translational Medicine: Path to Personalized and Public Health
Waldman, Scott A. , Terzic, André , Waldman, Scott A

Mayo Clinic

Biomarkers in Medicine | December 6, 2010 | Volume: 4 | Issue: 6 | Pages: 787-790

10.2217/bmm.10.101 | PMID 21133696 Get It

Percutaneous Cryoablation of Anterior Renal Masses: Technique, Efficacy, and Safety
Schmit, Grant D. , Atwell, Thomas D. , Leibovich, Bradley C. , Callstrom, Matthew R. , Woodrum, David A. , Charboneau, J. William, Kurup, A. Nicholas

Mayo Clinic

American Journal of Roentgenology | November 22, 2010 | Volume: 195 | Issue: 6 | Pages: 1418-1422

10.2214/ajr.09.3530 | PMID 21098204 Get It

Hb Cambridge-MA [β144(HC1)-β146(HC3)Lys-Tyr-His→0 (HBB c.433 A>T)]: A New High Oxygen Affinity Variant
Oliveira, Jennifer L. , Swanson, Kenneth C., Wendt, Patricia, Caughey, Thomas, Hoyer, James D., Herrick, Jennifer L.

Mayo Clinic

Hemoglobin | November 15, 2010 | Volume: 34 | Issue: 6 | Pages: 565-571

10.3109/03630269.2010.526921 | PMID 21077764 Get It

The Effect of Dutasteride on the Usefulness of Prostate Specific Antigen for the Diagnosis of High Grade and Clinically Relevant Prostate Cancer in Men With a Previous Negative Biopsy: Results From the REDUCE Study
Andriole, Gerald L. , Bostwick, David G., Brawley, Otis W. , Gomella, Leonard G. , Marberger, Michael, Montorsi, Francesco , Pettaway, Curtis A. , Tammela, Teuvo L.J. , Telöken, Cláudio , Tindall, Donald J., Freedland, Stephen J. , Somerville, Matthew C. , Wilson, Timothy H., Fowler, Ivy L., Castro, Ramiro, Rittmaster, Roger S., Group, REDUCE Study, Larcher, Alessandro , Group, REDUCE Study

Mayo Clinic

Journal of Urology | November 13, 2010 | Volume: 185 | Issue: 1 | Pages: 126-131

10.1016/j.juro.2010.09.011 | PMID 21074214 Get It

Initial development of Minnesota Multiphasic Personality Inventory–2–Restructured Form (MMPI–2–RF) scales to identify patients with psychogenic nonepileptic seizures
Locke, Dona E.C. , Thomas, Michael L. , Locke, Dona E C

Mayo Clinic

Journal of Clinical and Experimental Neuropsychology | November 12, 2010 | Volume: 33 | Issue: 3 | Pages: 335-343

10.1080/13803395.2010.518141 | PMID 21069613 Get It

Immunosuppressive CD14+HLA-DRlow/− monocytes in B-cell non-Hodgkin lymphoma
Lin, Yi , Bulur, Peggy A. , Gastineau, Dennis A. , Dietz, Allan B. , Gustafson, Michael P. , Witzig, Thomas E. , Dietz, Allan B , Lin, Yi

Mayo Clinic

Blood | November 10, 2010 | Volume: 117 | Issue: 3 | Pages: 872-881

10.1182/blood-2010-05-283820 | PMID 21063024 Get It

AbstractImmunosuppression is a known risk factor for B-cell non-Hodgkin lymphoma (NHL), yet mechanisms of tumor-associated immunosuppression remain to be fully characterized. We examined the immunophenotype of 40 NHL patients and 27 age-matched healthy volunteers to better understand systemic immune suppression. NHL peripheral blood mononuclear cells had significantly decreased interferon-γ production and proliferation. This suppression was not the result of regulatory T cells, interleukin-6 or interleukin-10, as these factors were not different between NHL and healthy volunteers (controls). We were able to restore T-cell proliferation by removing NHL monocytes, suggesting that these monocytes are suppressive. This suppression was mediated in part through arginine metabolism as exogenous arginine supplementation partially overcame monocytes' suppression of T-cell proliferation in vitro and NHL patients had elevated arginase I in their plasma. NHL monocytes had impaired STAT1 phosphorylation and interferon-α production to CpG stimulation and a dendritic cell differentiation deficiency. Further studies demonstrated that monocytes from NHL patients had decreased HLA-DR and Tumor necrosis factor-α receptor II (CD120b) expression compared with controls (CD14+HLA-DRlow/−CD120blow). Patients with increased ratios of CD14+HLA-DRlow/− monocytes had more aggressive disease and suppressed immune functions. In summary, we report that CD14+HLA-DRlow/− monocytes are a major and multifactorial contributor to systemic immunosuppression in NHL.
The Ability of Biomarkers to Predict Systemic Progression in Men with High-Risk Prostate Cancer Treated Surgically Is Dependent on ERG Status
Karnes, R. Jeffrey , Cheville, John C. , Sebo, Thomas J., Nair, Asha, Tang, Hui, Munz, Jan-Marie, Kosari, Farhad , Vasmatzis, George , Ida, Cristiane M.

Mayo Clinic

Cancer Research | November 10, 2010 | Volume: 70 | Issue: 22 | Pages: 8994-9002

10.1158/0008-5472.can-10-1358 | PMID 21062978 Get It

Abstract The objective of this study was to assess the relationship of the tumor protein levels of TOP2A and MIB-1 and ERG status with cancer-specific outcomes in men with high-risk prostate cancer treated by radical prostatectomy (RP). A 150-pair case-control study was designed from RP patients who developed systemic progression (SP) within 6 years of RP (cases) and men who were free of disease at least 8 years after RP (controls). The cases and controls were matched on conventional prognostic clinical parameters. TOP2A and MIB-1 levels were assessed by immunohistochemical methods, and ERG status was assessed by quantitative reverse transcription-PCR. The prognostic abilities of TOP2A and MIB-1 were significantly better in ERG(−) patients, and TOP2A was superior to MIB-1. In receiver operating characteristic analysis, the TOP2A and MIB-1 scores exhibited AUCs of 0.81 and 0.78 for ERG(−) patients, versus 0.67 and 0.68 for ERG(+) patients, respectively. Clinical parameters attained an AUC of 0.65 in ERG(−) patients and 0.54 in ERG(+) patients. When both markers were incorporated into a model for ERG(−) patients, the AUC increased to 0.83, with TOP2A showing a stronger association with SP than MIB-1. The time to SP was significantly associated with TOP2A; higher 5-year SP rates were observed in patients with higher TOP2A protein levels. In addition, although patient numbers are small, the response to adjuvant androgen deprivation therapy is associated with ERG status, showing more significant treatment effect in ERG(+) patients. Cancer Res; 70(22); 8994–9002. ©2010 AACR.
Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid–Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Central Cancer Treatment Group Study N05C5
Wolf, Sherry L., Qin, Rui , Menon, Smitha, Rowland, Kendrith M. , Thomas, Sachdev , Delaune, Robert, Christian, Diana L., Pajon, Eduardo R., Satele, Daniel , Loprinzi, Charles L. , Berenberg, Jeffrey L.

Mayo Clinic

Journal of Clinical Oncology | November 9, 2010 | Volume: 28 | Issue: 35 | Pages: 5182-5187

10.1200/jco.2010.31.1431 | PMID 21060036 Get It

Purpose Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated. This trial was conducted on the basis of preliminary data that a urea/lactic acid–based topical keratolytic agent (ULABTKA) may prevent HFS. Patients and Methods A randomized, double-blind phase III trial evaluated 137 patients receiving their first ever cycle of capecitabine at a dose of either 2,000 or 2,500 mg/m2 per day for 14 days. Patients were randomly assigned to a ULABTKA versus a placebo cream, which was applied to the hands and feet twice per day for 21 days after the start of capecitabine. Patients completed an HFS diary (HFSD) daily. HFS toxicity grade (Common Terminology Criteria for Adverse Events [CTCAE] v3.0) was also collected at baseline and at the end of each cycle. The primary end point was the incidence of moderate/severe HFS symptoms in the first treatment cycle, based on the patient-reported HFSD. Results The percentage of patients with moderate/severe HFS symptoms was not different between groups, being 13.6% in the ULABTKA arm and 10.2% in the placebo arm (P = .768 by Fisher's exact test). The odds ratio was 1.37 (95% CI, 0.37 to 5.76). Cycle 1 CTCAE skin toxicity was higher in the ULABTKA arm but not significantly so (33% v 27%; P = .82). No significant differences were observed in other toxicities between groups. Conclusion These data do not support the efficacy of a ULABTKA cream for preventing HFS symptoms in patients receiving capecitabine.
Germline Variation in Apoptosis Pathway Genes and Risk of Non–Hodgkin's Lymphoma
Kelly, Jennifer L., Novak, Anne J. , Fredericksen, Zachary S., Liebow, Mark , Ansell, Stephen M. , Wang, Alice H., Call, Timothy G. , Cerhan, James R. , Doǧan, Ahmet , Witzig, Thomas E. , Kay, Neil E. , Habermann, Thomas M. , Slager, Susan L. , Cerhan, James R

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 8, 2010 | Volume: 19 | Issue: 11 | Pages: 2847-2858

10.1158/1055-9965.epi-10-0581 | PMID 20855536 Get It

Abstract Background: The t(14;18)(q32;q21) translocation is the most commonly observed chromosomal translocation in non–Hodgkin's lymphoma (NHL), resulting in constitutive Bcl-2 expression and apoptosis inhibition. In addition, germline variation in both BCL2L11 (BIM) and CASP9, known regulators of apoptosis, has recently been linked to NHL risk. We conducted a comprehensive evaluation of 36 apoptosis pathway genes with risk of NHL. Methods: We genotyped 226 single-nucleotide polymorphisms (SNP) from 36 candidate genes in a clinic-based study of 441 newly diagnosed NHL cases and 475 frequency-matched controls. We used principal components analysis to assess gene-level associations, and logistic regression to assess SNP-level associations. MACH was used for imputation of SNPs in BCL2L11 and CASP9. Results: In gene-level analyses, BCL2L11 (P = 0.0019), BCLAF1 (P = 0.0097), BAG5 (P = 0.026), and CASP9 (P = 0.0022) were associated with NHL risk after accounting for multiple testing (tail strength, 0.38; 95% confidence interval, 0.05-0.70). Two of the five BCL2L11 tagSNPs (rs6746608 and rs12613243), both genotyped BCLAF1 tagSNPs (rs797558 and rs703193), the single genotyped BAG5 tagSNP (rs7693), and three of the seven genotyped CASP9 tagSNPs (rs6685648, rs2020902, and rs2042370) were significant at P < 0.05. We successfully imputed BCL2L11 and CASP9 SNPs previously linked to NHL, and replicated all four BCL2L11 and two of three CASP9 SNPs. Conclusion: We replicated the association of BCL2L11 and CASP9 with NHL risk at the gene and SNP level, and identified novel associations with BCLAF1 and BAG5. Impact: Closer evaluation of germline variation of genes in the apoptosis pathway with risk of NHL and its subtypes is warranted. Cancer Epidemiol Biomarkers Prev; 19(11); 2847–58. ©2010 AACR.